IGM Biosciences Past Earnings Performance
Past criteria checks 0/6
IGM Biosciences's earnings have been declining at an average annual rate of -40.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 85.9% per year.
Key information
-40.5%
Earnings growth rate
61.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 85.9% |
| Return on equity | -121.2% |
| Net Margin | -11,568.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20
We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Revenue & Expenses BreakdownBeta
How IGM Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -246 | 50 | 0 |
| 30 Sep 23 | 2 | -238 | 50 | 26 |
| 30 Jun 23 | 2 | -234 | 50 | 26 |
| 31 Mar 23 | 2 | -229 | 50 | 25 |
| 31 Dec 22 | 1 | -221 | 50 | 0 |
| 30 Sep 22 | 1 | -219 | 50 | 12 |
| 30 Jun 22 | 0 | -205 | 47 | 12 |
| 31 Mar 22 | 0 | -185 | 43 | 17 |
| 31 Dec 21 | 0 | -165 | 38 | 0 |
| 30 Sep 21 | 0 | -139 | 32 | 20 |
| 30 Jun 21 | 0 | -115 | 27 | 35 |
| 31 Mar 21 | 0 | -95 | 22 | 52 |
| 31 Dec 20 | 0 | -81 | 18 | 4 |
| 30 Sep 20 | 0 | -72 | 16 | 58 |
| 30 Jun 20 | 0 | -61 | 14 | 51 |
| 31 Mar 20 | 0 | -53 | 12 | 44 |
| 31 Dec 19 | 0 | -43 | 9 | 35 |
| 30 Sep 19 | 0 | -37 | 7 | 30 |
| 30 Jun 19 | 0 | -34 | 6 | 27 |
| 31 Mar 19 | 0 | -27 | 5 | 22 |
| 31 Dec 18 | 0 | -23 | 4 | 19 |
Quality Earnings: IGMS is currently unprofitable.
Growing Profit Margin: IGMS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IGMS is unprofitable, and losses have increased over the past 5 years at a rate of 40.5% per year.
Accelerating Growth: Unable to compare IGMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IGMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IGMS has a negative Return on Equity (-121.25%), as it is currently unprofitable.